Search Results | Cancer Research | American Association for Cancer Research

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Abstract LB-015: Differential therapeutic responses of MET oncogenic activations to Met kinase inhibitor and neutralizing antibody

Jianqun Kou, Ben Staal, Phillip R. Musich, Liang Kang, Yuan Qin, Zhi Q. Yao, Boheng Zhang, Tam Angela, Alan Huang, Huaixiang Hao, George F. Vande Woude, Qian Xie

Cancer Res (2018) 78 (13_Supplement): LB-015.

DOI: https://doi.org/10.1158/1538-7445.AM2018-LB-015

Published: 01 July 2018

View article

Journal Articles

Abstract 2896: Genomic determinants and signature of MET-targeted therapy in glioblastoma.

Qian Xie, Jennifer Johnson, Maria Libera Ascierto, Liang Kang, Robert Bradley, Sandeep Mittal, Kyle Furge, Michael Briggs, Kirk Tanner, Michael E. Berens, Francesco M. Marincola, George F. Vande Woude

Cancer Res (2013) 73 (8_Supplement): 2896.

DOI: https://doi.org/10.1158/1538-7445.AM2013-2896

Published: 15 April 2013

View article

Journal Articles

Abstract 2167: Strengthening anti-cancer effects on non-small cell lung carcinoma by dual blockage of MET and EGFR in a context-dependent manner.

Yu-Wen Zhang, Ben Staal, Curt Essenburg, Steven Lewis, Dafna Kaufman, George F. Vande Woude

Cancer Res (2013) 73 (8_Supplement): 2167.

DOI: https://doi.org/10.1158/1538-7445.AM2013-2167

Published: 15 April 2013

View article

Journal Articles

Abstract 4092: Cancer-type regulation of MIG-6 expression by 5-Aza-2′-deoxycytidine and Trichostatin A

Yu-Wen Zhang, Ben Staal, George F. Vande Woude

Cancer Res (2012) 72 (8_Supplement): 4092.

DOI: https://doi.org/10.1158/1538-7445.AM2012-4092

Published: 15 April 2012

View article

Journal Articles

Abstract LB-223: Dissecting the therapeutic determinants of MET inhibition in Glioblastoma: HGF-autocrine loop predicts sensitivity to MET inhibitor

Qian Xie, Robert Bradley, Liang Kang, Julie Koeman, Andrea Worschech, Valeria De Giorgi, Ena Wang, Lisa Kefene, Yanli Su, Curt Essenburg, Dafna Kaufman, Tom DeKoning, Mark Enter, Timothy J.O'Rourke, Francesco Marincola, George F. Vande Woude

Cancer Res (2011) 71 (8_Supplement): LB-223.

DOI: https://doi.org/10.1158/1538-7445.AM2011-LB-223

Published: 15 April 2011

View article

Journal Articles

Abstract LB-39: Phenotypic switching and molecular anatomy of malignant progression (E-M-T/M-E-T).

Chong-Feng Gao, George F. Vande woude

Cancer Res (2011) 71 (8_Supplement): LB-39.

DOI: https://doi.org/10.1158/1538-7445.AM2011-LB-39

Published: 15 April 2011

View article

Journal Articles

MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor–Dependent Fashion to Suppress Carcinoma Growth

Yu-Wen Zhang, Ben Staal, Curt Essenburg, Yanli Su, Liang Kang, Rich West, Dafna Kaufman, Tom DeKoning, Bryn Eagleson, Sean G. Buchanan, George F. Vande Woude

Cancer Res (2010) 70 (17): 6880–6890.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-0898

Published: 31 August 2010

View article

Includes: Supplementary data

Journal Articles

Abstract 2316: Epithelial to mesenchymal transition: Interplay between E-Cadherin and HGF/SF-Met signaling

Chong-Feng Gao, Elizabeth A. Haak, Yanli Su, Eric Hudson, Karl Dykema, George F. Vande Woude, George F. Vande Woude

Cancer Res (2010) 70 (8_Supplement): 2316.

DOI: https://doi.org/10.1158/1538-7445.AM10-2316

Published: 15 April 2010

View article

Journal Articles

Abstract 3256: Investigating the intrinsic signaling differences in MET- and ERBB2-driven breast cancers

Carrie R. Graveel, Jack D. DeGroot, Karl Dykema, Robert E. Sigler, Kyle A. Furge, George F. Vande Woude

Cancer Res (2010) 70 (8_Supplement): 3256.

DOI: https://doi.org/10.1158/1538-7445.AM10-3256

Published: 15 April 2010

View article

Journal Articles

Abstract LB-118: 17AAG, through hydrophobic binding, targets mitochondrial VDAC and inhibits cell invasion

Qian Xie, Robert Wondergem, Yuehai Shen, Greg Cavey, Jiyuan Ke, Ryan Thompson, Robert Bradley, Yong Xu, Jennifer Holtrop, Hanan Omar, David Wenkert, Eric Xu, George F. Vande Woude

Cancer Res (2010) 70 (8_Supplement): LB-118.

DOI: https://doi.org/10.1158/1538-7445.AM10-LB-118

Published: 15 April 2010

View article

Journal Articles

The Decline in U.S. Cancer Mortality in People Born since 1925

Eric J. Kort, Nigel Paneth, George F. Vande Woude

Cancer Res (2009) 69 (16): 6500–6505.

DOI: https://doi.org/10.1158/0008-5472.CAN-09-0357

Published: 12 August 2009

View article

Includes: Supplementary data

Journal Articles

c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion

Kenjiro Sawada, A. Reza Radjabi, Nariyoshi Shinomiya, Emily Kistner, Hilary Kenny, Amy R. Becker, Muge A. Turkyilmaz, Ravi Salgia, S. Diane Yamada, George F. Vande Woude, Maria S. Tretiakova, Ernst Lengyel

Cancer Res (2007) 67 (4): 1670–1679.

DOI: https://doi.org/10.1158/0008-5472.CAN-06-1147

Published: 16 February 2007

View article

Journal Articles

Antibody Microarray Profiling Reveals Individual and Combined Serum Proteins Associated with Pancreatic Cancer

Randal Orchekowski, Darren Hamelinck, Lin Li, Ewa Gliwa, Matt VanBrocklin, Jorge A. Marrero, George F. Vande Woude, Ziding Feng, Randall Brand, Brian B. Haab

Cancer Res (2005) 65 (23): 11193–11202.

DOI: https://doi.org/10.1158/0008-5472.CAN-05-1436

Published: 01 December 2005

View article

Includes: Supplementary data

Journal Articles

RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and Survival

Nariyoshi Shinomiya, Chong Feng Gao, Qian Xie, Margaret Gustafson, David J. Waters, Yu-Wen Zhang, George F. Vande Woude

Cancer Res (2004) 64 (21): 7962–7970.

DOI: https://doi.org/10.1158/0008-5472.CAN-04-1043

Published: 01 November 2004

View article

Journal Articles

HGF/SF–Met mediated angiogenesis occurs through the dual regulation of VEGF and TSP–1

Yu-Wen Zhang, Yanli Su, Olga V. Volpert, George F. Vande Woude

Cancer Res (2004) 64 (7_Supplement): 596.

Published: 01 April 2004

View article

Journal Articles

Novel geldanamycin target involved in the inhibition of theHGF/MET pathway

Qian Xie, Chong Feng Gao, Nariyoshi Shinomiya, Margaret Gustafson, Edward A. Sausville, David Wenkert, Yuehai Shen, George F. Vande Woude

Cancer Res (2004) 64 (7_Supplement): 1238.

Published: 01 April 2004

View article

Journal Articles

Tumorigenic effects of activating Met mutations in a knock-in mouse model

Carrie R. Graveel, Yanli Su, Ling-Mei Wang, Michele Fiscella, Lino Tessarollo, Carmen Birchmeier, Roderick T. Bronson, George F. Vande Woude

Cancer Res (2004) 64 (7_Supplement): 1177.

Published: 01 April 2004

View article

Journal Articles

Application of c-met siRNA adenoviruses to cancer gene therapy

Nariyoshi Shinomiya, Chong Feng Gao, Qian Xie, Yu-Wen Zhang, Margaret Gustafson, George F. Vande Woude

Cancer Res (2004) 64 (7_Supplement): 275.

Published: 01 April 2004

View article

Journal Articles

Met Protein Expression Level Correlates with Survival in Patients with Late-stage Nasopharyngeal Carcinoma

Chao-Nan Qian, Xiang Guo, Brian Cao, Eric J. Kort, Chong-Chou Lee, Jindong Chen, Ling-Mei Wang, Wei-Yuan Mai, Hua-Qing Min, Ming-Huang Hong, George F. Vande Woude, James H. Resau, Bin Tean Teh

Cancer Res (2002) 62 (2): 589–596.

Published: 01 January 2002

View article

Journal Articles

The Geldanamycins Are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network

Craig P. Webb, Curtis D. Hose, Shahriar Koochekpour, Michael Jeffers, Marianne Oskarsson, Edward Sausville, Anne Monks, George F. Vande Woude

Cancer Res (2000) 60 (2): 342–349.

Published: 01 January 2000

View article

NARROW

Abstract LB-015: Differential therapeutic responses of MET oncogenic activations to Met kinase inhibitor and neutralizing antibody

Abstract 2896: Genomic determinants and signature of MET-targeted therapy in glioblastoma.

Abstract 2167: Strengthening anti-cancer effects on non-small cell lung carcinoma by dual blockage of MET and EGFR in a context-dependent manner.

Abstract 4092: Cancer-type regulation of MIG-6 expression by 5-Aza-2′-deoxycytidine and Trichostatin A

Abstract LB-223: Dissecting the therapeutic determinants of MET inhibition in Glioblastoma: HGF-autocrine loop predicts sensitivity to MET inhibitor

Abstract LB-39: Phenotypic switching and molecular anatomy of malignant progression (E-M-T/M-E-T).

MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor–Dependent Fashion to Suppress Carcinoma Growth

Abstract 2316: Epithelial to mesenchymal transition: Interplay between E-Cadherin and HGF/SF-Met signaling

Abstract 3256: Investigating the intrinsic signaling differences in MET- and ERBB2-driven breast cancers

Abstract LB-118: 17AAG, through hydrophobic binding, targets mitochondrial VDAC and inhibits cell invasion

The Decline in U.S. Cancer Mortality in People Born since 1925

c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion

Antibody Microarray Profiling Reveals Individual and Combined Serum Proteins Associated with Pancreatic Cancer

RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and Survival

HGF/SF–Met mediated angiogenesis occurs through the dual regulation of VEGF and TSP–1

Novel geldanamycin target involved in the inhibition of theHGF/MET pathway

Tumorigenic effects of activating Met mutations in a knock-in mouse model

Application of c-met siRNA adenoviruses to cancer gene therapy

Met Protein Expression Level Correlates with Survival in Patients with Late-stage Nasopharyngeal Carcinoma

The Geldanamycins Are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only